Discovery of new breast cancer gene may lead to improved diagnostics and further progress in personalized therapy

Research published in Science Translational Medicine using Genome-Wide Analysis Studies (GWAS) has shown that the breast CpG island methylator phenotype (B-CIMP) is associated with improved survival and low metastatic risk.

Sally Church in an insightful post on Pharma Strategy Blog discusses what these findings mean.

She concludes that this research could be “an amazing discovery in the development of breast cancer research and treatment and may spur further innovation through improved targeted agents, diagnostics and patient selection.”

If you are interested in breast cancer, you should check out Sally’s post on Pharma Strategy Blog.

 

error: Content is protected !!